Pathology MCQs for various entrance exams

Welcome to your LUNG TUMORS MCQs based on Latest WHO updates

1. KRAS mutations are found in non-small cell lung carcinomas. Which of the following statements is NOT correct?

A. KRAS mutations are less commonly seen among Asian descents.

B. KRAS mutations are more commonly seen among non-smokers.

C. Patients with KRAS mutations seem to have a poorer prognosis.

D. Patients with KRAS mutations seem to be resistant to EGFR tyrosine kinase inhibitor therapy.

2. Which of the following statements regarding EGFR mutations is CORRECT?

A. EGFR mutations are often found in adenocarcinoma with micropapillary and/or the lepidic growth pattern.

B. EGFR mutations are not found in Asian patients.

C. Tumors with EGFR mutation have a poor response to EGFR tyrosine kinase inhibitor therapy.

D. EGFR mutation can be detected in a tumor with KRAS mutations.

3. Rearrangements of the gene encoding anaplastic lymphoma kinase ( ALK gene rearrangements) have been found in a subset of lung adenocarcinomas. Which of the following statements is CORRECT?

A. The most common ALK rearrangement in nonsmall cell lung carcinoma is EML4 – ALK fusion.

B. EML4 – ALK rearrangements are found in tumor with KRAS mutations.

C. EML4 – ALK rearrangements are found in tumor with EGFR mutations.

D. EML4 – ALK rearrangements are more common found in adenocarcinomas of heavy smokers.

4. Which of the following statements is NOT correct?

A. Mutation and overexpression of the EGFR gene lead to cancer cell overgrowth, but not tumor progression.

B. Mutations of the EGFR gene lead to cancer cell overgrowth and tumor progression.

C. Mutations of the EGFR gene stimulate tyrosine kinase activity.

D. Erlotinib and gefi tinib are tyrosine kinase inhibitors (TKIs) that target the EGFR signaling pathway.

LUNG TUMORS MCQs based on Latest WHO updates

Like this:

Comments

Leave a Reply Cancel reply

LUNG TUMORS MCQs based on Latest WHO updates

Share this:

Like this:

Comments

Leave a Reply Cancel reply